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Perspective
Can I be sued for that? Liability risk and the disclosure
of clinically significant genetic research findings
Amy L. McGuire,1,4 Bartha Maria Knoppers,2 Ma’n H. Zawati,2 and Ellen Wright Clayton3
1Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas 77030, USA; 2Centre of Genomics and Policy,
McGill University, Montreal, Quebec H3A 0G1, Canada; 3Center for Biomedical Ethics and Society, Vanderbilt University, Nashville,
Tennessee 37203, USA
Genomic researchers increasingly are faced with difficult decisions about whether, under what circumstances, and how to
return research results and significant incidental findings to study participants. Many have argued that there is an
ethical—maybe even a legal—obligation to disclose significant findings under some circumstances. At the international
level, over the last decade there has begun to emerge a clear legal obligation to return significant findings discovered
during the course of research. However, there is no explicit legal duty to disclose in the United States. This creates legal
uncertainty that may lead to unmanaged variation in practice and poor quality care. This article discusses liability risks
associated with the disclosure of significant research findings for investigators in the United States.
The return of individual research results and incidental findings to
participants in genome research has stimulated extensive policy
discussion and intense scholarly debate over the past several years.
In the context of genome-wide research, it has been identified as
one of the most pressing ethical challenges warranting immediate
policy attention (Caulfield et al. 2008). Several professional bodies,
in the United States and abroad, have published ethics recom-
mendations suggesting an obligation to offer at least some in-
dividual research results to participants (National Bioethics Advi-
sory Council 1999; Council for International Organizations of
Medical Sciences 2002; United Nations Educational, Scientific and
Cultural Organization 2003; Knoppers et al. 2006; Fabsitz et al.
2010; Office of Biorepositories and Biospecimen Research 2010;
Cassa et al. 2012; World Medical Association 2013). Despite this,
research suggests that genome scientists are not routinely returning
research results or incidental findings to study participants (Heaney
et al. 2010; Fullerton et al. 2012; McGuire et al. 2013; Ramoni et al.
2013). A survey of genome-wide association study (GWAS) inves-
tigators suggests that the fear of legal liability serves as both a mo-
tivation and a barrier to the return of results (Ramoni et al. 2013). On
the one hand, investigators are concerned about their potential lia-
bility for failure to return results. In fact, Hank Greely suggests that
not offering to return results may be illegal, at least in extreme cir-
cumstances where the results ‘‘pose a very high risk of a serious
disease’’ (Greely 2007). On the other hand, investigators worry that
they could be sued for adverse outcomes resulting from premature
disclosure, the disclosure of inaccurate findings, or medical mis-
management resulting from disclosure. Yet, no United States regu-
lations directly address this issue, and there is no clear case law to rely
on. This creates legal uncertainty that may lead to unmanaged var-
iation in practice and poor quality care (Wennberg 2004).
This article focuses on the disclosure of research results and
clinically significant incidental findings (hereinafter ‘‘significant
findings’’) in the context of genetic research. We do not address the
equally important and controversial issue of potential liability re-
lated to disclosure of incidental findings in the clinical context. We
also focus specifically on genomic research but recognize that the
liability issues are similar for other areas of research, such as neu-
roimaging research, where investigators are likely to discover clini-
cally significant findings in the research context. We therefore look
to case law in these other areas to help inform our analysis.We limit
our discussion to findings that the researcher has knowledge of.
Some have argued that there is a moral duty to hunt for significant
findings, at least in the clinical context (Evans 2013). For example,
the American College of Medical Genetics and Genomics (ACMG)
recently published ‘‘Recommendations on Incidental Findings for
Clinical Exome and Genome Sequencing’’ (Green et al. 2013) that
suggests that clinical laboratories have a duty to seek out certain
genetic variants that meet a high threshold of clinical utility. The
recommendations are limited explicitly to clinical sequencing, and
we do not think they should apply to research because of important
differences between the nature of research and clinical care, whichwe
describe elsewhere (Clayton and McGuire 2012) and summarize be-
low. However, the authors of the ‘‘Recommendations’’ recognize that
they may inform the development of research standards (Green et al.
2013). To the extent that they becomewidely adopted by the genome
research community, they could create a new standard of care.
Finally, we limit our analysis to United States law. At the in-
ternational level, over the last decade there has begun to emerge
a clear legal obligation to return significant findings discovered
during the course of research (Table 1). The European Convention
onHuman Rights and Biomedicine (OviedoConvention), as well as
several national laws, indicate the emergence of a legal obligation to
disclose andmake arrangements for the communication of research
results, including its meaning for both individuals and their fami-
lies. Individuals who engage in research internationally should be
aware of these laws and are responsible for complying with them.
No explicit legal duty to disclose in the United States
United States federal regulations for the protection of human re-
search subjects (the ‘‘Common Rule’’; Code of Federal Regulations)
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do not specifically require the return of research results or clinically
significant incidental findings. The Common Rule does require
that investigators disclose to research participants the reasonably
foreseeable risks and benefits of participating in the research and,
when appropriate, findings developed during the course of the
research that may relate to the subject’s willingness to continue
participation (Code of Federal Regulations). It could be argued that,
at a minimum, this requirement obligates investigators to disclose
the fact that significant findings might be discovered during the
course of the research and whether or not those will be offered to
subjects and/or their physicians. If specific findings might in-
fluence the subject’s willingness to continue participation in the
research, then theremay be a duty to offer those results (Wolf et al.
2008). Ultimately, the statutory authority to ensure regulatory
compliance and decide if a specific finding might influence a sub-
ject’s willingness to continue participation and thus must be of-
fered rests with the investigator’s institutional review board (IRB).
Yet, a recent study of IRB professionals reports that many IRB
members are not comfortable with their expertise in genomic re-
search, and few have actual experience addressing the issue of
return of genetic research results (Dressler et al. 2012). Further, the
Office of Human Research Protections (OHRP) has never directly
addressed this issue, leaving IRBs with little guidance tomake their
determinations.
In addition to disclosing the risks and benefits of research, the
Common Rule also requires researchers to minimize risks and en-
sure that these are reasonable in relation to the anticipated bene-
fits. This suggests that investigators at least ought to have a plan for
how to deal with significant findings to ensure that the risks of
disclosure or nondisclosure are minimized (Wolf et al. 2008). It
does not, however, create an obligation to disclose.
United States case law does not help clarify the legal obliga-
tions of researchers. No court has addressed directly the issue of
a researcher’s legal duty to disclose significant findings discovered
during the course of research (Clayton et al. 2013). Nor have the
courts addressed whether clinical geneticists have a legal duty to
disclose incidental findings discovered during the course of routine
genetic testing. Although not directly on point, there are eight legal
cases involving claims of medical malpractice related to incidental
findings from clinical radiologic imaging that may provide some
guidance (Clayton et al. 2013). In three cases, the physician was
found not to have breached the duty of care. Of the other five cases,
only one (Lo v. Burke 1995) resulted in a finding of physician lia-
bility. The other four cases were likely settled.
Negligence as a cause of action for nondisclosure
Although there are several legal theories under which a researcher
could be sued for failure to disclose significant findings (Tovino
2008; Bush and Rothenberg 2012), the most probable cause of
action is ordinary negligence. Negligence is defined legally as
‘‘conduct which falls below the standard established by law for
the protection of others against unreasonable risk of harm’’ (Re-
statement [second] of torts 1965). In order to prove negligence, the
plaintiff must show that the defendant owed a duty to the plaintiff
that was breached and caused compensable damages (Restatement
[second] of torts 1965; Goldberg and Zipursky 2001). In order to
determine whether a duty was breached, the courts look to what
the standard of care is. The standard of care is defined typically by
prevailing professional practice; that is, what would a reasonable
researcher do under similar circumstances. This is established
typically through expert testimony, which often relies on pro-
fessional practice, published literature, and professional guidance
documents (Clayton and McGuire 2012).
Also relevant is the nature of the relationship between the
researcher and the participant. Legal obligations are generally role
specific. Legal duties in research are therefore different from legal
duties in clinical practice, and the legal duties of researchers vary
depending on the nature of the relationship between the inves-
tigator and the participant. The physician–patient relationship is
a fiduciary relationship, or a relationship held in trust (Zeigler v.
Illinois Trust & Savings Bank 1910; Bowman v. McPheeters 1947;
Adams v. Ison 1952; Stafford v. Shultz 1954; American Jurisprudence
1972; Fure v. Sherman Hospital 1978). This creates special obligations
for physicians to use their competence and skill to act primarily for
the benefit of their patient (McCullough 2013). Researchers, on the
other hand, have not traditionally been treated as fiduciaries (Moore
v. Regents of the University of California 1990; Greenberg v. Miami
Children’s Hospital Research Institute 2003; Tovino 2008) because, as
researchers, their primary obligation is to produce generalizable
Table 1. International laws on return of research results and significant incidental findings
Council of Europe, Convention for the Protection
of Human Rights and Dignity of the Human Being
with Regard to the Application of Biology and
Medicine: Convention on Human Rights
and Biomedicine, ETS no. 164 Oviedo,
4.IV.1997 (ratified by 29 countries to date)
1997 ‘‘Everyone is entitled to know any information collected about his or her
health’’ (article 10)
Council of Europe, Additional Protocol to the
Convention on Human Rights and Biomedicine,
concerning Biomedical Research, CETS no. 195
Strasbourg, 25.I.2005
2005 Required that researchers make ‘‘arrangements for access to information
relevant to the participant arising from the research and to its overall
results’’ (article 13.2[v]); moreover, ‘‘if research gives rise to information
of relevance to the current or future health or quality of life of research
participants, this information must be offered to them. . .’’ (emphasis
added) (article 27)
Estonia, Human Genes Research Act, 2000 2000 Gave donors ‘‘the right to access personally their data stored in
GeneBank’’ (article 11.2)
Spain, Law 14/2007 of 3 July on Biomedical
Research, 2007
2007 Mandates not only ‘‘the right to be informed of his or her genetic data’’
but also ‘‘the right not to know’’; irrespective of the choice not to know,
however, such data would be communicated ‘‘to avoid serious damage
to his health or that of his biological family members. . .’’ (article 5)
Taiwan, Human Biobank Management Act, 2010 2010 Requires ‘‘participants to be made aware of any possible impacts of the
genetic information derived from the biological specimens on the
participant, and his/her relatives or ethnic group’’ (article 7.8)
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knowledge, even if it requires actions that are not primarily for the
benefit of the individual research subject. In some cases, health
professionals have dual roles as physicians who are also conduct-
ing research on their patients. Although the law clearly distin-
guishes the individual’s role-specific obligations, in reality it is
sometimes difficult to separate the two.
Physicians who enroll their patients into research have an
inherent conflict of interest. Their primary obligation as a re-
searcher to ensure scientific integrity and create generalizable
knowledge may, at times, conflict with their primary obligation as
a physician to protect and promote their patient’s health interests.
This conflict is managed typically through the informed consent
process in which the patient/participant is being asked to suspend
the clinical relationship for a research relationship, as long as it
does not significantly interfere with the patient’s health interests.
For example, consider a physician/researcher who is conducting
a placebo-controlled trial for the off-label use of a drug that she
believes will benefit patients with mild cognitive impairment, and
her patient with mild cognitive impairment is randomized to re-
ceive the placebo. The physician/researcher is discouraged (typi-
cally by being blinded herself to the randomization process) from
removing the patient/participant from the trial in order to pre-
scribe the study drug because this would undermine the research
process and make it impossible to systematically assess the risks
and benefits of new drugs or new indications for existing phar-
maceuticals. Keeping the participant in the study does not violate
the physician’s fiduciary responsibility to her patient because, al-
though the physician believes the study drug will be more effica-
cious, there is not yet sufficient evidence to support this belief,
creating clinical equipoise (Freedman 1987), which justifies the
appropriateness of a scientific study in the first place. On the flip
side, if the patient/participant is randomized to the study drug
and experiences a significant adverse event, then the physician/
researcher has an obligation, as a physician and a researcher, to
report the event and discontinue study participation.
In the context of genetic research, the type of research being
done, the ways in which the research data are collected and stored,
and the nature of the relationship between researcher and partic-
ipant can all weigh heavily in determining liability. For example, it
is unlikely that investigators will have an opportunity to discover
clinically significant findings related to an individual when con-
ducting population-based research that explores genomic varia-
tion in the aggregate. The risk of liability is therefore more limited
in that context than when the research questions focus on in-
terrogation of an individual’s genome. Likewise, investigators who
conduct research using anonymized data that cannot be traced
back to an individual would not feasibly be able to return signifi-
cant findings discovered during the course of the research and
therefore should not be liable for failure to do so. Those partici-
pants who agree to the anonymized use of their data also likely
have a heightened expectation of privacy that ought to be
respected. With regard to the nature of the relationship, researchers
who also have a physician/patient relationship with study partici-
pants may be more likely to have the professional competence and
expertise to judge materiality of genomic information for medical
decision-making, by considering it in the larger context and taking
into considerationother test results, signs and symptomsdiscovered
on physical examination, comorbidities, family history, and envi-
ronmental exposures. For this reason, the courts may bemore likely
to find that physician/researchers who enroll their patients into the
research have a higher duty to disclose relevant and significant
findings.
It would be much more difficult to prove that a researcher
who does not have a physician–patient relationship with the
participant has a duty to disclose significant findings discovered
during the course of the research. However, there may be a com-
mon law duty to rescue by disclosing a much higher threshold of
immediately actionable findings. Except in limited circumstances, an
individual generally has no duty to assist or obtain help for persons
in distress or to warn of imminent danger (Keeton 1984). Yet, there
are several exceptions to this rule when a legal duty to aid may be
imposed, including ‘‘where one stands in a certain relationship to
another’’ (State v. Miranda 1998). Whether and under what circum-
stances such a special relationship exists in research is unsettled.
Several commentators (Miller et al. 2008; Richardson 2008; Wolf
et al. 2008) and one court (Grimes v. Kennedy Krieger Institute Inc.
2001) have suggested a ‘‘special relationship’’ evolves from certain
interactions between a researcher and subject that may give rise to
heightened obligations. The one court case that has suggested that
a special relationship may exist in research implies that it arises
from the ‘‘very nature of nontherapeutic scientific research on
human subjects’’ (Grimes v. Kennedy Krieger Institute Inc. 2001). This
case has been heavily criticized, but one might nonetheless con-
clude that, to the extent a special relationship is recognized, it will
be limited to investigators enrolling subjects into research and
according to the terms of their consent forms.
Although it has never been directly addressed by the courts, it
is difficult to imagine that a special relationship giving rise to
a duty to rescue would be found based solely on the fact that the
investigator is conducting research using a biological specimen
from the subject, if they have not ever personally interacted with
one another and the investigator has no way of knowing who the
individual who provided the specimen is. The legal obligations of
investigators who are conducting research using stored specimens
and data should therefore be limited to those that are contractually
created by the storage facility through appropriate use agreements,
such as material transfer agreements, data use agreements, and
memoranda of understanding.
Scholars have suggested other theories of liability, such as the
theory of partial entrustment, in which even downstream re-
searchers owe a duty of ancillary care to subjects because those
subjects entrust relevant aspects of their health to researchers by
waiving their rights to privacy with regard to their health infor-
mation during the informed consent process (Richardson andCho
2012). However, this theory has been criticized because research
does not aim to promote individual health, and creating obli-
gations of ancillary care would compromise the central mis-
sion of researchers to produce generalizable knowledge (Garrett
2013). There is also no case law to support the application of
theories like partial entrustment to return of results in research
(Tovino 2008).
Liability for negligent disclosure
Researchers also worry about potential liability associated with
disclosure. Researchers who disclose significant findings (regard-
less of whether they have a duty to disclose) must do so compe-
tently and in a way that is consistent with standard practice. This
requires that they comply with standards that seek to maximize
the analytic and clinical validity of findings. For example, research
laboratories often have less stringent standards for quality and
accuracy than clinical diagnostic laboratories. Methods for doc-
umenting the chain of custody of samples are more rigorous in
clinical laboratories because the consequences of a sample swap are
Researchers’ l iability risk
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more severe. It is required therefore, at least in the United States,
that research results are validated in a clinically certified laboratory
prior to return ‘‘for the diagnosis, prevention or treatment of any
disease or impairment of, or the assessment of the health of in-
dividuals’’ (Meyers 2011). If a researcher returns erroneous results
that have not been validated without making clear that the results
need to be repeated before any clinical interventions are un-
dertaken, and if that error results in compensable harm to a sub-
ject, then the researcher may be liable for negligence. Similarly,
researchers who deviate from standard practice regarding variant
calling and interpretation may be exposed to liability. Of course,
as is true with any new technology, the standards are evolving
rapidly, and there are many limitations in the ability to interpret
accurately genomic data. Investigators should not be held le-
gally accountable for errors in interpretation that can reason-
ably be expected given the novelty of the science, as long as
subjects are informed of the limitations and associated risks.
Again, the burden of proof will rest with the subject to prove
that the researcher’s actions fell below the standard of care and
that those actions resulted in compensable harm to the subject.
However, absent clearly defined and agreed upon standards,
and given that there is still fervent debate about how to interpret
variants and what, if any, results ought to be returned and how,
it will be extremely difficult to prove what the standard of care
is or that it has clearly been breached by a researcher acting in
good faith.
Conclusion
In conclusion, there is very little legal precedent to determine the
parameters of researchers’ risk of liability at this point in time.
Nonetheless, we can expect to see more litigation in this area, due
in part to increasing public awareness and in part to numerous
proposals, some of which are quite far reaching, to impose such
responsibility on actors in the research enterprise (Wolf et al.
2012). The legal obligations of researchers will depend very much
on the type of research being done, the ways in which the research
data are collected and stored, and the researcher’s relationshipwith
the study participant, as well as emerging consensus on appro-
priate professional behavior. Guidelines, recommendations, and
policy statements that are published by professional societies or
groups of experts usually include a disclaimer that they are not
intended to represent the standard of care. However, in the case of
a lawsuit, both parties will rely on those documents to establish
professional practice and define the obligations of researchers. The
research community needs to be aware of the potential legal im-
pact of these professional statements and should consider all of the
ramifications when writing them and before embracing them,
formally and in practice.
Leaving this issue to litigation will likely result in in-
consistency across jurisdictions and court rulings that may not
take into account the full complexity of the issue. Federal regula-
tion could limit litigation by indemnifying investigators for failure
to return results, while allowing them to do so when, in their
professional judgment andwith approval from an IRB, it is deemed
ethically appropriate. Yet, there is no indication that this is on the
horizon. For example, the United States Department of Health and
Human Services is in the process of proposing substantial changes
to the federal regulation of human subjects research (ANPRM
2011), but none of the proposed changes directly address this
important issue. Absent regulatory protection, the fear of liability
has a tendency to drive behavior. In the end, however, researchers
should concern themselvesmore with the responsible stewardship
of genomic data then with potential liability for their actions.
Acting in good faith and using one’s professional expertise tomake
good judgments are always the best defense.
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